arrow
C

Cengiz Karaçin

university of health sciences
H指数:11
被引数:546

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world comparison of doxorubicin–ifosfamide versus gemcitabine–docetaxel regimens in metastatic uterine leiomyosarcoma: a multicenter retrospective study

晚期子宫平滑肌肉瘤中多柔比星–异环磷酰胺与吉西他滨–多西他赛方案的真实世界比较:一项多中心回顾性研究

2025-11-170
OAAI
Efficacy and safety of doxorubicin–ifosfamide versus gemcitabine–docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study

多中心真实世界研究:多柔比星–异环磷酰胺方案与吉西他滨–多西他赛方案作为一线疗法治疗晚期非子宫平滑肌肉瘤的疗效与安全性比较

2025-10-280
PRE
Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

卡博替尼与舒尼替尼在晚期非透明细胞肾细胞癌中的真实世界比较:土耳其肿瘤学集团的多中心研究

2025-09-010
PRE
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

尿酸盐水平在转移性肾细胞癌接受纳武利尤单抗治疗中的研究:一项土耳其肿瘤学组肾癌联盟(TKCC)研究

2025-07-030
PRE
The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium

吸烟对纳武利尤单抗治疗肾细胞癌结局的影响:土耳其肿瘤学组肾癌联盟的真实世界数据

2025-07-010
PRE
Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

在转移性肾细胞癌中 navigat ing二线疗法:免疫检查点抑制剂与酪氨酸激酶抑制剂的比较分析:土耳其肿瘤学组肾癌联盟的研究

2025-04-240
OA
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

舒尼替尼在转移性肾细胞癌中的应用:土耳其肿瘤学组肾癌协作组中不同风险组的临床结局

2025-02-101
OAAI
Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

黑色素瘤的辅助和一线转移治疗的预后因素和结果土耳其肿瘤学组研究

2025-01-250
OAAI
Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

细胞周期蛋白依赖性激酶抑制剂后依维莫司加激素治疗的疗效; 现实生活经验,TOG研究

2024-08-090
PRE